TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Telbivudine and Lamivudine to Prevent Vertical Transmission of Hepatitis B

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age: 20-40 years old~2. HBsAg, HBeAg positive and HBV DNA \>6 log10 copies/ml~3. Gestational age: 26-28 weeks with normal fetus~4. Willing to consent for the study~Exclusion Criteria:~1. Elevated ALT~2. Antiviral treatment experience patients~3. Co-infection with HAV, HCV,HDV, HIV~4. Concurrent treatment with immune modulators, cytotoxic drugs, or steroids~5. Clinical signs of threatened miscarriage in early pregnancy~6. Clinical evidence of cirrhosis and/or hepatocellular carcinoma

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Telbivudine (Type: EXPERIMENTAL): Mother receives telbivudine 600mg per day. Infant receives standard immunoprophylaxis
- Lamivudine (Type: EXPERIMENTAL): Mother receives lamivudine 100mg per day. Infant receives standard immunoprophylaxis.
- No antiviral treatment (Type: NO_INTERVENTION): Mother receives no antiviral treatment. Infant receives standard immunoprophylaxis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics and Dynamics of Dexmedetomidine as Adjuvant in TAP Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 24 ASA I-II~* patients (age 18-60 years~* weight 50-89 kg~Exclusion Criteria:~* a known allergy to the study drugs~* significant cardiac~* respiratory, renal or hepatic diseases~* bleeding diathesis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine group (Type: ACTIVE_COMPARATOR): patients were given ultrasound guided TAP-block with 20 ml of 0.5 % bupivacaine + dexmedetomidine 1 μg•kg-1 diluted in 20 ml saline
- bupivacaine group (Type: PLACEBO_COMPARATOR): patients will given ultrasound guided TAP-block with 20 ml of 0.5 % bupivacaine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Mometasone to Reduce Painful Episodes in Patients With Sickle Cell Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 15 or older~* Sever SCD phenotypes (Hb SS and Sβthalassemia0)~* A positive response to cough/wheeze questions~Exclusion Criteria:~* Patient carries a physician diagnosis of asthma~* Patient is prescribed asthma medications~* Patient is currently having a painful crisis (as defined by validated pain diary questions)~* Patient has acute respiratory symptoms~* Known hypersensitivity to milk proteins~* Meets criteria for our operational diagnosis of asthma~* More than 15 ED visits for pain over the preceding 12 months~* Admitted or discharged from the hospital for SCD pain within the last 7 days

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mometasone Furoate (Type: EXPERIMENTAL): 1 puff daily (220mcg) for 16 weeks
- Placebo (Type: PLACEBO_COMPARATOR): 1 puff daily for 16 weeks. Training inhaler that does not contain any medication (placebo).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Evaluate The PDE10 Enzyme Occupancy Following A Single Dose Of PF-02545920 In Healthy Male Volunteers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* healthy male volunteers~Exclusion Criteria:~* History of orthostatic hypotension~* History of prior radiation exposure for research purposes, or radiation therapy

- Gender: MALE
- Minimum Age: 21 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 - 20 mg (Type: EXPERIMENTAL): Cohort will include 4 HVs/completers who will receive a single 20 mg dose of PF-02545920.
- Cohort 2 ( adaptive dose, optional) (Type: EXPERIMENTAL): Cohort 2 will include 4 HVs/completers who will receive a single dose of PF-02545920. The dose will be selected based on the results obtained for Cohort 1.
- Cohort 3 ( adaptive dose, optional) (Type: EXPERIMENTAL): Cohort 3 will include 4 HVs/completers who will receive a single dose of PF-02545920. The dose will be selected based on the results obtained for Cohort 1.~Dose options range from 30 mg to 10 mg, 5 mg, 2mg, 1 mg. This cohort is optional

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients diagnosed with schizophrenia or schizoaffective disorder who are currently taking olanzapine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of GW685698X 100mcg Administered Once Daily Either in the Morning or the Evening and GW685698X 250mcg Administered Once Daily in the Evening Via DISKHALER for 28 Days in Subjects With Persistent Bronchial Asthma.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatients aged between 16- 65 years.~* Male and female; female subjects must be non-child bearing potential or of childbearing potenetial with negative pregnancy test and willing to use acceptable contraceptive methods~* Documented clinical history of persistent asthma first diagnosed at least 6 months prior to Visit 1~* Currently receiving inhaled short-acting beta-2 agonists for symptom relief~* A lung function of between 50 to 90% predicted (PEF)~* Increase in PEF of at least15%, 20 minutes after inhalation of 400mcg salbutamol~Exclusion Criteria:~* History of respiratory tract infection and/or exacerbation of asthma within a period of 4 weeks prior to Visit 1~* History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnoea, respiratory arrest or hypoxia seizures.~* A history of two or more asthma exacerbations requiring treatment with oral corticosteroids or hospitalisation in the 6 months before Visit 1.~* Past or present disease that, as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, haematologic disease, neurological disease, endocrine disease or pulmonary disease (including, but not confined to, chronic bronchitis, emphysema, bronchiectasis with the need of treatment, cystic fibrosis and bronchopulmonary dysplasia).~* Known or suspected sensitivity to corticosteroids, VENTOLIN, or the constituents of ROTADISKS (e.g., lactose).~* Undergoing allergen desensitisation therapy.~* Neurological or psychiatric disease or history of drug or alcohol abuse that would interfere with the subject's proper completion of the protocol requirements.~* Is a current smoker or has a smoking history of 10 pack years or more (e.g., 20 cigarettes/day for 10 years). Note: Current smoker is defined as currently smoking or stopped smoking within 6 months of screening visit.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- GW685698X (fluticasone furoate) 100mcg Morning (Type: EXPERIMENTAL): None
- GW685698X (fluticasone furoate) 100mcg Evening (Type: EXPERIMENTAL): None
- GW685698X (fluticasone furoate) 250mcg Evening (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas Aeruginosa

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 18 years of age~* Patients under intensive care management with hospital acquired pneumonia~* Microbiological diagnosis of P. aeruginosa serotype O11 HAP by lower respiratory tract specimen (BAL or miniBAL) and presence of a new or progressing pulmonary infiltrate, plus one of the three following criteria: a) fever greater than 38ºC, b) WBC greater than 10,000/mm3, or c) purulent sputum~* In non-intubated patients confirmed microbiological diagnosis of P. aeruginosa serotype O11 HAP by endotracheal aspirate (ETA) and modified clinical pulmonary infection score (CPIS) higher than 6 points~* Patient is expected to survive longer than 72 hours~* Written informed consent provided by the patient or by the relatives or the designated trusted person~Exclusion Criteria:~* Use of any investigational drug within 30 days preceding the first dose of KBPA-101, or planned use during the study and safety follow-up periods~* Existence of any surgical or medical condition that might render the patient unduly susceptible to possible toxicity from the monoclonal antibody, including septic shock with unstable hemodynamics,~* Patients with a known complement deficiency associated with systemic lupus erythematosus, paroxysmal nocturnal hemoglobinuria, hereditary angioedema, membranoproliferative glomerulonephritis, collagen vascular disease, autoimmune hepatitis, primary biliary cirrhosis, scleroderma, or recurrent Neisserial infections~* Confirmed Human Immunodeficiency Virus (HIV) infection~* Transplant patients and/or simultaneous treatment with systemic immuno-suppressive drugs.~* Patients with a known liver function deficiency, e.g. associated with liver cirrhosis (Child Pugh B or C) or acute hepatitis~* Administration of poly- or mono-immunoglobulins within the three months preceding the first dose of study drug or planned administration during the study period~* Neutropenia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- KBPA-101, a monoclonal antibody (Type: EXPERIMENTAL): 1.2 mg/kg KBPA-101 i.v. infusion, 3 single doses, every third day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of a Depigmented Extract of Phleum in Local Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Local allergic rhinitis with sensitization to grass pollen~* Skin prick test and serum specific IgE negative to grass pollen.~* Positive Nasal allergen provocation test (NAPT) to grass pollen and/or positive nasal specific IgE to grass pollen.~* Written informed consent~Exclusion Criteria:~* Immunological diseases~* Heart diseases that limit the use of adrenaline. For example, severe hypertension or treatment with beta-blockers.~* Treatment with beta-blockers~* Severe psychological disorders~* Severe atopic dermatitis~* FEV1 \< 70% of reference value after treatment~* Hypersensitivity or intolerance to excipients and / or medication trial.~* Failure to adequately perform diagnostic tests or treatment.~* Sensitization to other allergens (perennial or seasonal) with clinical relevance for the subject and that may interfere in the evaluation of the response.~* Immunotherapy in the 5 years prior to their inclusion in the study.~* Pregnant women or at risk of pregnancy and lactating women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- DEPIGOID phleum (Type: ACTIVE_COMPARATOR): The active treatment arm receive active phleum pollen immunotherapy (Depigoid 100% phleum). Depigmented and polymerized allergen extract of Phleum pollen for subcutaneous injection.
- DEPIGOID Placebo & DEPIGOID Phleum (Type: PLACEBO_COMPARATOR): This arm receive DEPIGOID Placebo during the first year, and DEPIGOID Phleum during the second year of study.~DEPIGOID Placebo contains the same composition as in the active DEPIGOID Phleum with the only difference being the exclusion of the phleum pollen allergen extract.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have a diagnosis of open angle glaucoma (OAG) (including normal-tension glaucoma \[NTG\],pigmentary or pseudoexfoliative glaucoma), or ocular hypertension (OHT) in one or both eyes.~* Subjects must meet the following IOP requirements at Visit 3 (Eligibility, Day 0\[after washout for the subjects already on treatment\]): mean/median IOP ≥15 mmHg and ≤36 mmHg at 10 AM in at least 1 eye; and IOP ≤36 mmHg in both eyes.~* Subjects with a corrected Decimal visual acuity (VA) or a Best-Corrected Decimal Visual Acuity (BCVA) of 0.5 or better in both eyes.~Exclusion Criteria:~* Subjects who are unable to discontinue contact lens use during and for 15 minutes following instillation of study drug and during study visits.~* Subjects who are unable to discontinue other eye drop medications such as artificial tears for 15 minutes prior to and 15 minutes after instillation of study drug.~* Subjects with a central corneal thickness greater than 600 μm in either eye.~* Subjects with any condition that prevents reliable applanation tonometry in either eye.~* Subjects with advanced glaucoma with a mean deviation (MD) \< -12 dB, a history of split fixation, or a field loss threatening fixation in either eye.~* Subjects with any condition that prevents clear visualization of the fundus.~* Subjects who are monocular (fellow eye is absent).~* Subjects with aphakia in either eye.~* Subjects with an active corneal disease in either eye.~* Subjects with severe dry eye in either eye.~* Subjects with a history/diagnosis of a clinically significant or progressive retinal disease in either eye.~* Subjects with very narrow angles and subjects with angle closure congenital, or secondary glaucoma, and subjects with history of angle closure in either eye.~* Subjects with any intraocular infection or inflammation in either eye within 3 months prior to Visit 1 (Screening).~* Subjects with a history of ocular laser surgery in either eye within the 3 months (90 days) prior to Visit 1 (Screening).~* Subjects with a history of incisional ocular surgery or severe trauma in either eye within 3 months prior to Visit 1 (Screening).

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Latanoprostene Bunod (Type: EXPERIMENTAL): Latanoprostene bunod 0.024% instilled into the eye once daily (QD) over a 1-year treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Amoxicillin/Metronidazole Based Quadruple Therapy for Helicobacter Pylori Eradication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with non-investigated/functional dyspepsia or scarred peptic ulcer with indication of H pylori eradication treatment~* Ability and willingness to participate in the study and to sign and give informed consent~* confirmed H pylori infection by at least one of the following methods: C13-urea breath test, histology, rapid urease test or bacterial culture.~Exclusion Criteria:~* patients with peptic ulcer~* previous H. pylori eradication therapy~* Age below 18 years~* major systemic diseases~* previous gastric surgery~* pregnancy or breastfeeding~* allergy to any of the study drugs~* receipt of anti-secretory therapy, antibiotics or bismuth salts 4 weeks prior to inclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Amoxicillin/metronidazole (Type: EXPERIMENTAL): Amoxicillin/metronidazole-based quadruple therapy for 14 days: Lansoprazole 30mg bid, Bismuth Potassium Citrate 220mg bid, amoxicillin 1000mg bid, Metronidazole 400mg qid
- Amoxicillin/clarithromycin (Type: ACTIVE_COMPARATOR): Amoxicillin/clarithromycin-based quadruple therapy for 14 days: Lansoprazole 30mg bid, Bismuth Potassium Citrate 220mg bid, Amoxicillin 1000mg bid, Clarithromycin 500mg bid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Center-involved macular edema secondary to CRVO for no longer than 3 months (at the screening visit it should be ensured that the subjects will comply with the criterion of ≤ 3 months since onset of macular edema at their scheduled baseline visit).~* Adult subjects diagnosed with macular edema secondary to CRVO who are scheduled to be treated with IVT aflibercept as per investigator's routine treatment practice with the intent to use a T\&E regimen after initial dosing.~* Treatment-naïve subjects for macular edema secondary to CRVO.~* Men and women ≥ 18 years of age.~* Documented BCVA of ETDRS letter score of 73 to 24 letters (Snellen equivalent of 20/40 to 20/320) in the study eye.~Exclusion Criteria:~* Previous PRP or macular laser photocoagulation in the study eye.~* Any prior or concomitant ocular treatment (e.g. anti-VEGF therapy, corticosteroids) in the study eye for macular edema secondary to RVO, except dietary supplements or vitamins prior to inclusion in the study. Intraocular anti-VEGF treatment is permitted for the treatment of diseases of fellow eye except for those that are specifically excluded.~* Prior systemic anti-VEGF or corticosteroid therapy, investigational or approved, within the last 3 months before the first dose in the study.~* Previous use of intraocular corticosteroids in the study eye at any time or use of periocular corticosteroids in the study eye within 12 months prior to Day 1.~* Any active intraocular, extraocular, and periocular inflammation or infection in either eye within 4 weeks of screening.~* Any history of allergy to povidone iodine.~* Known serious allergy to the fluorescein sodium for injection in angiography.~* Presence of any contraindications indicated in the EU commission/locally approved label for IVT aflibercept: hypersensitivity to the active substance IVT aflibercept or to any of the excipients; active or suspected ocular or periocular infection; active severe intraocular inflammation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intravitreal (IVT) aflibercept (Type: EXPERIMENTAL): Participants with macular edema secondary to CRVO were treated with the study drug intravitreal aflibercept

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete